<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827579</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/11/0519</org_study_id>
    <secondary_id>2013-000872-14</secondary_id>
    <secondary_id>MR/K007491/1</secondary_id>
    <nct_id>NCT01827579</nct_id>
  </id_info>
  <brief_title>Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)</brief_title>
  <acronym>ICAT</acronym>
  <official_title>Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the administration of allodepleted donor T
      cells to patients with haematological malignancies after stem cell transplant can improve the
      recovery of the patients immune system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating CD3+ve T cell count at 4 months post-SCT</measure>
    <time_frame>4 months post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV acute and chronic GVHD</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of normal T-cell (&gt;700/uL) and CD4 (&gt;300/uL) counts and normal TCR diversity as assessed by Vb spectratyping</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vitro anti-viral responses of circulating PBMC</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality at 1 year post-SCT</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival at 1 year post-SCT</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Haematological Malignancies</condition>
  <arm_group>
    <arm_group_label>CD25/71 allodepleted donor T-cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (normal HSCT)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD25/71 allodepleted donor T-cells</intervention_name>
    <description>CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant</description>
    <arm_group_label>CD25/71 allodepleted donor T-cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥16 years

          -  Underlying haematological malignancy

          -  Planned allogeneic peripheral blood stem cell transplantation from a 10/10 or 9/10 HLA
             matched unrelated donor, using an Alemtuzumab-based conditioning protocol

          -  Written Informed consent

        Exclusion Criteria:

          -  Life expectancy &lt; 6 weeks

          -  Female patients who are pregnant and lactating

          -  Patients who are serologically positive for Hepatitis B, C or HIV pre-SCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Persis Amrolia</last_name>
    <role>Study Chair</role>
    <affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ICAT trial manager</last_name>
    <phone>020 7679 9860</phone>
    <email>ctc.ICAT@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bilyana Popova</last_name>
    <phone>0207 679 9379</phone>
    <email>b.popova@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Peggs</last_name>
      <email>karl.peggs@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Karl Peggs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Tholouli</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>CD25/71 allodepleted donor T cells</keyword>
  <keyword>Infection</keyword>
  <keyword>Acute Myeloid Leukaemia</keyword>
  <keyword>Acute Lymphoblastic Leukaemia</keyword>
  <keyword>Adult</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

